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POCUS ISSUE: CARDIAC RESYNCHRONIZATION THERAPY
here Is Plenty of Room for
ardiac Resynchronization Therapy
evices Without Back-Up Defibrillators
n the Electrical Treatment of Heart Failure
. Claude Daubert, MD, FACC, Christophe Leclercq, MD, PHD, Philippe Mabo, MD
ennes, France
Patients with chronic heart failure might benefit from electrical therapy with a view to
resynchronize the heart and improve its mechanical performance by cardiac resynchronization
therapy (CRT) or to prevent the risk of sudden death by automatic defibrillation. These two
therapies can be applied separately or with a combined device, the biventricular implantable
cardioverter-defibrillator (CRT-D). There is currently no strong scientific evidence indicating
that a CRT-D must be offered to all candidates for CRT. Plain common sense should limit
the prescription of these costly devices for patients in need of secondary prevention or for
younger patients without major comorbidities. The preferential choice of CRT pacemakers in
the remainder of patients is currently a logical one. (J Am Coll Cardiol 2005;46:2204–7)
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.034© 2005 by the American College of Cardiology Foundation
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catients with chronic heart failure (CHF) might benefit
rom electrical therapy with a view to: 1) resynchronize the
eart and improve its mechanical performance, or 2) prevent
he risk of sudden death by automatic defibrillation. These
wo therapies can be applied separately with dedicated
evices, using a specific pacemaker for cardiac resynchroni-
ation therapy (CRT-P), or an implantable cardioverter-
efibrillator (ICD), or a combined device, the cardiac
esynchronization therapy by biventricular defibrillation
CRT-D). The article by Ellenbogen et al. (1) in this issue
f the Journal is a strong plea in favor of the preferential, if
ot exclusive, prescription of CRT-D for patients with
HF and cardiac dyssynchrony. We have a different opin-
on, which we share here in the light of available scientific
nformation, and on the basis of plain common sense.
HOCK-ONLY ICD THERAPY LOWERS
ORTALITY IN CHF: YES. . . BUT!
he use of ICDs for primary prevention is based on the
igh proportion of cardiac sudden deaths in CHF. This
ercentage, observed in the control groups of large drug
rials on New York Heart Association (NYHA) functional
lass II to IV patients ranges between 35% and 50%,
eaching a maximum of 58% in the Metoprolol Random-
zed Intervention Trial in Congestive Heart Failure
MERIT-HF) (2), which is probably explained by its
nclusion of 41% of patients in NYHA functional class II.
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Manuscript received August 4, 2005, accepted August 9, 2005.s the severity of CHF increases, the proportion of sudden
eath relative to overall mortality decreases, and conversely,
he percentage of deaths attributed to worsening heart
ailure increases (2). Therefore, the potentially greatest
enefit of ICDs is likely to be conferred to patients with
ild to moderate heart failure. The Sudden Cardiac Death
n Heart Failure (SCD-HeFT) trial is thus far the only trial
howing a lowering of all-cause mortality by ICD therapy in
atients with CHF and a left ventricular (LV) ejection
raction (EF) 35% (3). In that study, which enrolled
atients optimally treated for CHF, ICD therapy was
ompared with amiodarone or placebo. Although amioda-
one conferred no benefit compared with placebo, a signif-
cant 23% relative reduction in the risk of overall mortality
RRR) was observed among the ICD recipients. These
pparently spectacular results must be interpreted cau-
iously. The demographic characteristics of the SCD-HeFT
opulation were quite peculiar (see later text). In addition,
he trial had to include over 2,500 patients followed up for
median of 45.5 months and had to be extended for one
ear to show a statistically significant albeit modest absolute
isk reduction (ARR) of 7.2% at five years. Finally, in
greement with the epidemiologic data mentioned earlier, a
ubgroup analysis showed that the risk reduction was
imited to functional class II patients (RRR, 46%; ARR,
1.9% at five years). No treatment benefit was observed
mong the 30% of patients who were in NYHA functional
lass III (hazard ratio, 1.16). These latter observations,
hich place the impact of ICD therapy in perspective, must
lso have been considered when choosing a device for a
ardiac resynchronization therapy (CRT) candidate, be-
ause CRT has only been validated in NYHA functional
lass III to IV patients.
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December 20, 2005:2204–7 CRT With or Without ICDRT IS THE ONLY ELECTRICAL
HERAPY PROPERLY VALIDATED IN
ATIENTS WITH MODERATE TO SEVERE CHF
everal randomized trials have been conducted to ascertain
he clinical impact of CRT in patients with advanced CHF
nd in sinus rhythm, with or without indications for an ICD
4–11). Two meta-analyses have also been published
12,13). The usual enrolment criteria have been: 1) NYHA
unctional class III or IV function despite optimal drug
reatment, 2) LVEF 35%, and 3) QRS duration 120 or
150 ms.
The concordant results of these studies have confirmed
hat in this patient population, CRT combined with opti-
al pharmacologic therapy has a highly favorable and
ustained impact (13,14) on all of the treatment objectives:
) improvement of symptoms and exercise capacity with a
ean decrease in NYHA functional class by 0.5 to 0.8
oints, a mean increase in exercise capacity by 10% (VO2
eak) to 20% (6-min walking distance) and a highly
ignificant improvement in quality-of-life score; 2) major
eduction in heart failure-related morbidity with, in partic-
lar, a 30% to 52% decrease in the number of hospitaliza-
ions for worsening heart failure (10–13); 3) reverse ven-
ricular remodeling: a consistent finding in the randomized
rials designed with6 months of follow-up has been an up
o 15% absolute reduction in LV end-diastolic diameter,
nd an up to 6% increase in LVEF, conferred by CRT
11,14,15)—these effects were significantly greater in pa-
ients with non-ischemic than in patients with ischemic
eart disease (14,15); and 4) impact of CRT on mortality:
he CARE-HF and Comparision of Medical Therapy,
acing, and Defibrillation in Heart Failure (COMPAN-
ON) trials examined the effects of CRT on morbidity and
ortality (10,11). In the COMPANION trial (10), CRT-P
nd CRT-D were both associated with a 20% reduction in
he primary combined end point of all-cause mortality and
ll-cause hospitalization (p  0.01). However, only
RT-D, compared with controls, was associated with a
ignificant decrease in total mortality at one year (RRR,
Abbreviations and Acronyms
ARR  absolute risk reduction
CHF  chronic heart failure
CRT-D  cardiac resynchronization therapy by
biventricular defibrillation
CRT-P  pacemaker for cardiac resynchronization
therapy
EF  ejection fraction
ICD  implantable cardioverter-defibrillator
LV  left ventricular
NYHA  New York Heart Association
RRR  relative reduction in the risk of overall
mortality6%; ARR, 7%; p  0.003), whereas the 24% relative sabsolute, 4%) reduction in mortality associated with
RT-P was nearly statistically significant (p  0.059). The
ARE-HF trial enrolled 813 patients (11). The CRT-P
lus standard CHF pharmacologic treatment was compared
ith pharmacologic treatment alone. At the end of a mean
ollow-up of 29 months, a 37% relative risk reduction in the
omposite end point of death and hospitalization for major
ardiovascular events (p  0.001) and 36% in the risk of
eath (ARR, 10%; p  0.002) were observed. The effect on
ortality was mainly attributable to a marked reduction in
HF-related deaths. It is, however, noteworthy that the
bsolute number of sudden cardiac deaths was lower in the
RT group (n  29) than in the control group (n  38).
Recently, this scientific evidence has allowed the issue of
class I recommendation for CRT in the European Society
f Cardiology guidelines on the diagnosis and treatment of
hronic CHF to be formulated as follows: “CRT using
i-ventricular pacing can be considered in patients with
educed ejection fraction and ventricular dyssynchrony
QRS width 120 ms), who remain symptomatic in
YHA functional class III to IV despite optimal medical
herapy to improve symptoms (class or recommendation I,
evel of evidence A), hospitalizations (class I, level A) and
ortality (class I, level B)” (16).
N CHF PATIENTS WITH
NDICATION FOR CRT, WHICH TYPE OF
EVICE TO IMPLANT IN 2005: CRT-D OR CRT-P?
n practice, the question is whether the more complicated
nd costly device (i.e., CRT-D) offers a significant addi-
ional benefit compared with CRT-P. The COMPANION
rial is the only trial that has addressed this question,
lthough it, unfortunately, remains unresolved (10). This
ailure is explained by: 1) a median follow-up limited to 14
onths per study design, and 2) the absence of a direct
omparison between the two therapies, because the analysis
ompared CRT-P and CRT-D each with the control
roup. Therefore, the only tenable conclusion is that com-
ared with controls, CRT-D and CRT-P had a similar
ffect on all-cause mortality and hospitalization. It is also
oteworthy that a putative superiority of CRT-D was
hort-lived, because the survival curves of patients treated
ith CRT-P and CRT-D became parallel beyond the ninth
onth of follow-up. Only a new randomized study com-
aring the two treatment modalities might resolve this issue.
ased on the results of the CARE-HF trial (11), and
ssuming that the combination of CRT and defibrillation
ack-up could prevent two-thirds of sudden deaths, a study
ould require 1,300 patients per group and a follow-up
eriod equivalent to that of the CARE-HF trial to have a
tatistical power of 90% to detect a 5% absolute relative risk
eduction of death from any cause with the use of combined
herapy compared with CRT alone. Who will undertake
uch a study?
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CRT With or Without ICD December 20, 2005:2204–7ID THE PATIENTS INCLUDED IN THE
OMPANION TRIAL HAVE CHF THAT WAS TOO
DVANCED TO SHOW A BENEFIT FROM THE ICD?
s suggested by the SCD-HeFT study, the benefit con-
erred by ICDs might have been greater in a population
uffering from less severe CHF. On the other hand, the
fficacy of CRT has not been established in patients in
YHA functional class I to II function. Such demonstra-
ion is likely to be lengthy and arduous because, a priori,
hese patients have few or no symptoms, are rarely hospi-
alized for decompensation, and have a low death rate when
ptimally treated. In fact, the main goals of treatment for
atients in NYHA functional classes I to II are largely
ifferent from those set for patients in class III to IV,
onsisting primarily of: 1) preventing disease and CHF
rogression and 2) lowering cardiac mortality, mainly sud-
en. These specific objectives need to be achieved by the
ursuit of specific end points, the most relevant being: 1) a
omposite of symptoms, morbidity, and mortality (17) and
) reverse remodeling. In the study by Higgins et al. (7), a
ignificant degree of reverse remodeling was observed after
ix months of CRT in a small subgroup of patients in
YHA functional class I to II, although the benefits were
ess prominent than in the much larger group of patients in
YHA functional class III to IV (7). Similar observations
ere made in the Multicenter Insync Randomized Clinical
valuation (MIRACLE ICD II) study (9). This small trial
andomly assigned NYHA functional class II patients to
RT versus no CRT, who all received a CRT-D for an
ccepted ICD indication. At the end of the six-month
linded period, there was no significant difference in the
rimary study objective, although a significant improvement
n the clinical composite end point was observed in the
roup assigned to CRT compared with the controls. These
bservations suggest that CRT might have a favorable
mpact on the outcome of patients with less advanced CHF
nd ventricular dyssynchrony. This issue now needs to be
urther examined in large randomized trials. The ongoing
esynchronization Reverses Remodeling in Asymptomatic
eft Ventricular Dysfunction (REVERSE) (18) and Mul-
icenter Automatic Defibrillator Implantation with Cardiac
esynchronization Therapy (MADIT-CRT) trials are not
xpected to yield their results before three to five years.
RE THE RESULTS OF
ANDOMIZED TRIALS APPLICABLE TO
HE REAL WORLD OF CHF MANAGEMENT?
andomized trials are often criticized for their enrollment
f highly selected patients, unlike those encountered in real
ife. This criticism is particularly applicable in the treatment
f CHF. Considering the large randomized studies of drugs
r devices in CHF conducted in the last three years, the
ean age of the populations was relatively young, between
0 and 67 years, and the proportion of women was small,etween 20% and 32%. The most striking example is the
CD-HeFT trial, with a population 60.1 years old on
verage and 23% women (3). These demographic charac-
eristics are vastly different from those of registries in which
he mean ages range between 71 and 78 years and the
roportion of women approaches 50% (19,20). It is there-
ore problematic to apply recommendations issued from
andomized trials to the general population of patients with
HF. Common sense dictates that these recommendations
ould have to be applied to similar or identical patients. In
he case of the SCD-HeFT trial example, the treatment
hould be offered to young or relatively young patients
ithout serious comorbidity. However, the majority of
atients with advanced CHF are older and have various
oncomitant disorders (19,20).
It is not morally wrong to address the issue of priority of
herapeutic objectives in this majority of patients with CHF,
hose prognosis remains poor despite all efforts. Improving
uality of life, lowering the rates of hospitalizations for
anagement of CHF, and preserving patient autonomy are
robably priorities. A treatment that moreover lowers mor-
ality and prolongs life under comfortable conditions, which
he CRT-P achieves at a modest cost, may be viewed as
uccessful.
ONCLUSIONS
oth CRT-P and CRT-D are electrical treatment modal-
ties that have been validated for the management of CHF.
here is currently no strong scientific evidence indicating
hat a CRT-D must be offered to all candidates for CRT.
lain common sense should limit the prescription of these
ostly and complicated devices for patients in need of
econdary prevention, or for the purpose of primary preven-
ion in younger patients without major comorbidities. The
referential choice of CRT-P in the remainder of patients,
ho represent the large majority of potential candidates for
RT, is currently a logical one.
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